ArticleAmerican journal of ophthalmology case reports2024
Rapidly progressive central retinal pigmented epithelium atrophy after Ivospemin (SBP-101) treatment for pancreatic adenocarcinoma.
Article in American journal of ophthalmology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We report a case of retinal toxicity induced by SBP-101, a polyamine inhibitor for the treatment of metastatic pancreatic adenocarcinoma, presenting as rapidly progressive bilateral central retinal pigmented epithelium (RPE) atrophy in a patient with a silent ocular history. Observations: A 69-year-old female patient with a metastatic pancreatic adenocarcinoma visited our retina clinic referring a 6-months history of blurred vision and progressive visual field loss. One year before, she started administration of SBP-101 combined with nab-paclitaxel and gemcitabine to treat her malignancy. Baseline ophthalmological examination showed bilateral healthy retina an 20/20 visual acuity (VA). After the second monthly cycle of SBP-101, the patient experienced significant visual loss in both eyes, with VA decreasing to 20/50 in right eye (RE) and to 20/40 in left eye (LE). In the suspect of a cancer associated retinopathy (CAR), the patient underwent bilateral injection of intravitreal slow-releasing dexamethasone, with poor clinical outcomes. Concomitant testing for anti-enolase and anti-recoverin antibodies gave negative results, while electroretinography showed borderline but within the limit values in both eyes. At 6 months, VA was 20/5000 in RE and 20/4000 in LE and the patient referred significant limitations in everyday life. Ultra-wide field fundus photography showed a bilateral, roundish area of irregular pigment loss involving the entire macula and extending beyond the arcades. Ultra-wide autofluorescence showed a central area of hypo-autofluorescence surrounded by a ring of alternating hyper- and hypo-autofluorescence areas. Optical coherence tomography showed bilateral atrophy of the subfoveal RPE and disruption of the ellipsoid zone. Optic disc examination was within the limits. No treatment was possible. Conclusion and Importance: In conclusion, ophthalmologists should be aware of the existence of a sight-threatening side effect of SPB-101 administration, since we highlighted a massive bilateral RPE atrophy rapidly developing after the second drug injection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.